Former Sky News presenter and quiz show host reveals stage 4 cancer diagnosis
Former Sky News presenter Dermot Murnaghan has revealed he has been diagnosed with cancer.
Murnaghan has been a news presenter at Independent Television News, BBC News and most notably Sky News.
The 67-year-old presented the BBC quiz show Eggheads between 2003 and 2014 before Jeremy Vine took over.
He has now revealed he is battling prostate cancer.
Some personal news……I've been diagnosed with Stage IV advanced prostate cancer I'm fortunate to have a simply outstanding medical team looking after me, who I can't thank enough - they are administering the best possible care with expertise, compassion and sensitivity.
— Dermot Murnaghan (@DermotMurnaghan) June 23, 2025
Taking to X, (formerly Twitter), he said: "Some personal news……I've been diagnosed with Stage IV advanced prostate cancer I'm fortunate to have a simply outstanding medical team looking after me, who I can't thank enough - they are administering the best possible care with expertise, compassion and sensitivity.
"I'm responding positively to their excellent treatment and feeling well. I'm blessed to be fortified by the monumental love and support of my wife, family and close friends.
"Needless to say my message to all men over 50, in high-risk groups, or displaying symptoms, is get yourself tested and campaign for routine prostate screening by the NHS.
"Early detection is crucial. And be aware, this disease can sometimes progress rapidly without obvious symptoms.
"I'm aiming to take part in Sir Chris Hoy's fundraising charity bike ride in Glasgow in September - please support it and join us if you can. Take care, everyone, Dermot."
A number of people rushed to send support to the newsreader.
One said: "I'm so sorry to hear this. Sending you love and all the best for your healing journey. I've always loved your work.
"Thank you for raising awareness and thinking of others at this difficult personal time."
Another added: "Sad to hear this Dermot but it sounds like you have a terrific family and support network and a great desire to battle through. Best wishes."
A third said: "So sorry to hear this, Dermot. Wishing you all the best."
Recommended reading:
Fern Britton recalls 'great fun' working with Phillip Schofield on This Morning
EastEnders legend Mo Harris's real life brother is a famous Oscar-winning actor
Iconic former ITV presenter left 'traumatised' after being assaulted and robbed
Dermot Murnaghan has been a news presenter at a number of different publishers, including CNBC Europe, Independent Television News (ITN) and BBC News.
He presented different news programmes on Sky News between 2007 and February 2023.
Murnaghan presented the afternoon rolling coverage live for Sky News when the monarch Queen Elizabeth II died.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fast Company
39 minutes ago
- Fast Company
Hims & Hers stock plummets after Novo Nordisk ends partnership over 'knock-off' Wegovy
This morning, the Danish pharmaceutical giant Novo Nordisk announced the abrupt end of its brief partnership with telehealth company Hims & Hers Health, Inc. (NYSE: HIMS), citing concerns over Hims & Hers' 'knock-off' weight loss drugs. Now, Hims & Hers' shares are plummeting as investors react to the news. It's the latest update in a somewhat volatile year for Hims & Hers. Just this April, the company's stock spiked after it initially announced a collaboration with Novo Nordisk that allowed Hims & Hers to sell Novo Nordisk's FDA-approved weight loss drug, Wegovy, through its platform. But less than two months later, that partnership is fracturing after Novo Nordisk's claim that Hims & Hers engaged in 'deceptive promotion and selling of illegitimate, knockoff versions of Wegovy that put patient safety at risk.' At the time of this writing, HIMS stock is down 32.6% since market open. Here's what to know about the break-up: The shortage that fueled knock-off Wegovy Back in 2022, the Food and Drug Administration (FDA) declared a shortage of GLP-1 medications including Ozempic and Wegovy. Under this shortage notice, pharmacies were permitted to make compounded versions of the brand name drugs using their active ingredient, semaglutide, and sell them at a lower cost. Hims & Hers was one company that took part in selling a compounded—and non-FDA-approved—version of Wegovy. Then, this February, the FDA announced that Ozempic and Wegovy were no longer categorized under a shortage. With the brand name drugs fully back on the market, the FDA gave compounders 60 to 90 days to stop making copies of the patented drugs. At the time, Hims & Hers stated in a regulatory filing that, while it saw pathways to continue offering access to certain compounded GLP-1s after the shortage, it could not 'guarantee that we will be able to continue offering these products in the same manner, to the same extent, or at all.' However, an analyst told Reuters that Hims & Hers appeared poised to continue selling compounded semaglutide using 'personalized doses' after the shortage officially ended. Why is Novo Nordisk cutting ties now? In the wake of the FDA's shortage notice, Hims & Hers announced in April that it was entering a 'long-term collaboration' with Novo Nordisk to offer Wegovy directly to its consumers. Now, though, Novo Nordisk is breaking off the commitment over claims that Hims & Hers has not acted fast enough to stop selling its compounded GLP-1. Other telehealth companies, like Ro and Noom, have similarly faced criticism for continuing to sell their own compounded GLP-1 despite agreements with Eli Lilly, the maker of Zepbound. In an email to Fast Company, a Novo Nordisk spokesperson explained that 'semaglutide compounding is permitted under US compounding laws only in rare instances,' adding that other companies it's working with have 'demonstrated a good faith effort to transition patients to authentic, FDA-approved Wegovy.' However, the spokesperson continued, 'after over one month into the collaboration, Hims & Hers Health, Inc. has failed to adhere to the law which prohibits mass sales of compounded drugs under the false guise of 'personalization' and are disseminating deceptive marketing that puts patient safety at risk. This is unacceptable and that is why we have decided to end the collaboration.' That personalization, involves offering the same drug; however, at different doses. In a press release published this morning, Novo Nordisk also noted that it is 'deeply concerned' about knock-off drugs 'made with foreign illicit active pharmaceutical ingredients.' 'Based on Novo Nordisk's investigation, the 'semaglutide' active pharmaceutical ingredients that are in the knock-off drugs sold by telehealth entities and compounding pharmacies are manufactured by foreign suppliers in China,' the release reads. 'According to a report from the Brookings Institute, FDA has never authorized or approved the manufacturing processes used by any of these foreign suppliers to make semaglutide, nor has FDA ever reviewed or authorized the quality of the 'semaglutide' they produce.' Hims & Hers did not immediately respond to Fast Company 's request for comment on Novo Nordisk's claims. On X, Novo Nordisk CEO Andrew Dudam said 'Novo Nordisk's commercial team increasingly pressured us to control clinical standards and steer patients to Wegovy regardless of whether it was clinically best for patients. We refuse to be strong-armed by any pharmaceutical company's anticompetitive demands that infringe on the independent decision making of providers and limit patient choice.' He went on to say 'We will continue to offer access to a range of treatments, including Wegovy, to ensure providers can serve the individual needs of patients.'
Health Line
an hour ago
- Health Line
What Are Intramuscular Injections?
An intramuscular injection is a technique for delivering medication deep into the muscles. This allows the medication to absorb quickly into the bloodstream. You may have received an intramuscular injection at a doctor's office the last time you got a vaccine, like the flu shot. In some cases, a person may also self-administer an intramuscular injection. For example, certain drugs that treat multiple sclerosis or rheumatoid arthritis may require self-injection. What are intramuscular injections used for? Intramuscular injections are a common practice in modern medicine. They're used to deliver drugs and vaccines. Several drugs and almost all injectable vaccines are delivered this way. Intramuscular injections are used when other types of delivery methods are not recommended. These include: oral (swallowed into the stomach) intravenous (injected into the vein) subcutaneous (injected into the fatty tissue just under the layer of skin) Intramuscular injections may sometimes be used instead of intravenous injections because some drugs are irritating to veins or because a suitable vein cannot be located. However, not all intravenous medications can be administered intramuscularly. They may be used instead of oral delivery because some drugs are destroyed by the digestive system when you swallow them. Intramuscular injections are absorbed faster than subcutaneous injections. This is because muscle tissue has a greater blood supply than the tissue just under your skin. Muscle tissue can also hold a larger volume of medication than subcutaneous tissue. Intramuscular injection sites Intramuscular injections are often given in the following areas: Deltoid muscle of the arm The deltoid muscle is the site most typically used for vaccines. However, this site is not common for self-injection because its small muscle mass limits the volume of medication that can be injected — typically no more than 1 milliliter. It's also challenging to use this site for self-injection. A caregiver, friend, or family member can assist with injections into this muscle. To locate this site, feel for the bone (acromion process) located at the top of your upper arm. The correct area to give the injection is two finger widths below the acromion process. At the bottom of the two fingers will be an upside-down triangle. Give the injection in the center of the triangle. Vastus lateralis muscle of the thigh The thigh may be used when the other sites are not available or if you need to administer the medication on your own. Divide the upper thigh into three equal parts. Locate the middle of these three sections. The injection should go into the outer top portion of this section. Ventrogluteal muscle of the hip The ventrogluteal muscle is the safest site for adults and children older than 7 months. It's deep and not close to any major blood vessels or nerves. However, this site is difficult for self-injection and may require the help of a friend, family member, or caregiver. Place the heel of your hand on the hip of the person receiving the injection, with your fingers pointing toward their head. Position your fingers so your thumb points toward their groin, and you feel the pelvis under your pinky finger. Spread your index and middle fingers in a slight V shape, and inject the needle into the middle of that V. Dorsogluteal muscles of the buttocks For many years, healthcare professionals most commonly selected the dorsogluteal muscle of the buttocks. However, due to the potential for injury to the sciatic nerve, the ventrogluteal muscle is most often used instead. This site in the dorsogluteal muscle is difficult to use for self-injection and is not recommended. You should not use an injection site that has evidence of infection or injury. If you'll be giving the injection more than once, rotate the injection sites to avoid injury or discomfort to the muscles. How to administer an intramuscular injection Anyone who administers intramuscular injections should receive training and education on proper injection techniques. The needle size and injection site will depend on many factors. These include the age and size of the person receiving the medication, and the volume and type of medication. Your doctor or pharmacist will give you specific guidelines about which needle and syringe are appropriate to administer your medication. The needle should be long enough to reach the muscle without penetrating the nerves and blood vessels underneath. Generally, needles should be 1 inch to 1.5 inches for an adult and will be smaller for a child. They'll be 22-gauge to 25-gauge thick, noted as 22g on the packaging. Follow these steps for a safe intramuscular injection: 1. Wash your hands Wash your hands with soap and warm water to prevent potential infection. Be sure to thoroughly scrub between your fingers, on the backs of your hands, and under your fingernails. The Centers for Disease Control and Prevention (CDC) recommends lathering for 20 seconds, which is the time it takes to sing the 'Happy Birthday' song twice. 2. Gather all the needed supplies Assemble the following supplies: needle and syringe with medication alcohol pads gauze puncture-resistant container to discard the used needles and syringe (typically a red, plastic sharps container) bandages 3. Locate the injection site To isolate the muscle and target where you'll place the injection, spread the skin at the injection site between two fingers. The person receiving the injection should get into a comfortable position that allows easy access to the location and keeps the muscles relaxed. 4. Clean the injection site Clean the site selected for injection with an alcohol swab and allow the skin to air dry. 5. Prepare the syringe with medication Remove the cap. If the vial or pen is multidose, note when the vial was first opened. The rubber stopper should be cleaned with an alcohol swab. Draw air into the syringe. Draw back the plunger to fill the syringe with air up to the dose that you'll be injecting. This is done because the vial is a vacuum, and you need to add an equal amount of air to regulate the pressure. This also makes it easier to draw the medication into the syringe. If you forget this step, you can still get the medication out of the vial. Insert air into the vial. Remove the cap from the needle and push the needle through the rubber stopper at the top of the vial. Inject all of the air into the vial. Be careful not to touch the needle to keep it clean. Withdraw the medication. Turn the vial and syringe upside down so the needle points upward, and pull back on the plunger to withdraw the correct amount of medication. Remove air bubbles. Tap the syringe to push any bubbles to the top and gently depress the plunger to push the air bubbles out. 6. Self-inject with a syringe Hold the needle like a dart and insert it into the muscle at a 90-degree angle. You should insert the needle in a quick but controlled manner. Do not push the plunger in. 7. Inject the medication Push the plunger slowly to inject the medication into the muscle. 8. Remove the needle Withdraw the needle quickly and discard it into a puncture-resistant sharps container. Do not put the cap back on the needle. A sharps container is a red container that you can purchase at any pharmacy. It collects medical waste, such as needles and syringes. You should not put these materials into the regular garbage, as needles can be hazardous to anyone who handles the trash. 9. Apply pressure to the injection site Use a piece of gauze to apply light pressure to the injection site. You can even massage the area to help the medication be absorbed into the muscle. It's routine to see slight bleeding. Use a bandage if necessary. Tips for an easier injection To minimize possible discomfort before your injection: Apply ice or an over-the-counter topical numbing cream to the injection site before cleaning it with the alcohol pad. Allow the alcohol to dry completely before the injection. Otherwise, it might cause stinging. Warm the vial of medication by rubbing it between your hands before drawing the medication into the syringe. Have someone you trust give you the injection. Some people find it difficult to inject themselves. What are the complications of intramuscular injections? It's typical to experience some discomfort after an intramuscular injection. However, certain symptoms may be signs of a more serious complication. Call your doctor or healthcare professional right away if you experience: You may have some anxiety about performing or receiving an injection, especially an intramuscular injection, due to the long needle. Read through the steps several times until you feel comfortable with the procedure, and take your time. You can ask your doctor or pharmacist to go through the procedure with you beforehand. They're more than willing to help you understand how to perform a safe, proper injection.
Yahoo
an hour ago
- Yahoo
Mounjaro becomes available on the NHS: what to know and what to do if you're not eligible
Obesity remains one of the most pressing, and preventable, health challenges of our time. The UK is one of a number of countries undoubtedly struggling with it. It affects nearly every organ system in the body, contributing to cardiovascular conditions like coronary heart disease; musculoskeletal issues such as osteoarthritis and gout; and even the development of certain cancers, including of the breast, uterus and colon. Its impact on mental health is also significant. A few years ago, injectable weight-loss drugs entered clinical use and quickly captured public attention for their ability to promote rapid fat loss. Ozempic is available on the NHS, but only for managing type 2 diabetes. Wegovy is authorised for weight loss and cardiovascular risk reduction and is also available on the NHS, though access is currently limited to specialist weight management services. Now, a new option has emerged: Mounjaro, which is approved for both type 2 diabetes and weight loss. This dual-purpose drug is now available on the NHS, offering another potential tool in the fight against obesity. Demand is expected to be high. However, access will be limited at first, with strict eligibility criteria for NHS prescriptions. Get your news from actual experts, straight to your inbox. Sign up to our daily newsletter to receive all The Conversation UK's latest coverage of news and research, from politics and business to the arts and sciences. Mounjaro (tirzepatide) is a once weekly injectable medication designed to help control blood-sugar levels. It works by boosting the secretion and effects of insulin, improving glycaemic control in people with Type 2 diabetes. It also slows gastric emptying — the process by which food leaves the stomach — and enhances feelings of fullness by acting on the brain. This combined effect reduces appetite and helps support weight loss. Compared to similar medications like Ozempic and Wegovy (both brand names for semaglutide), clinical trials found Mounjaro more effective, with some participants losing up to 20% of their body weight over a 72-week period. Read more: The NHS has introduced specific criteria to prioritise patients most in need. First, patients need a BMI of 40 or more (classified as morbid obesity). People from certain ethnic backgrounds, such as South Asian communities, may be eligible at a lower BMI due to higher clinical risk of health conditions. Second, at least four obesity-related health conditions must be diagnosed, including type 2 diabetes, hypertension (high blood pressure), dyslipidaemia (abnormal cholesterol or triglyceride levels), cardiovascular disease and obstructive sleep apnoea. (Some of these conditions often occur together; for example, high blood pressure and cholesterol.) Patients are encouraged to check their BMI and confirm their diagnoses before contacting a GP. This helps ensure appointments are used effectively and discussions remain focused. While the current criteria are strict, there is optimism that eligibility will broaden in the coming years to include people with lower BMIs and fewer co-morbidities. The NHS continues to offer a comprehensive weight-loss programme, tiered according to BMI and previous attempts at weight loss. Don't underestimate the value of group-based programmes or community referrals – when a healthcare professional refers a patient to a community-based health service for further care or support – many of which can be accessed via your GP. These services, such as the NHS digital weight management programme, support both individuals and families and can be highly effective for sustainable fat loss. GPs may also refer patients to online courses and structured exercise programmes. Lifestyle interventions, including increased physical activity and healthier eating, remain cornerstones of obesity treatment and are critical for long-term success, even when medications are used. Read more: Higher tier interventions may be considered if lifestyle changes fail or if the patient has significant co-morbidities. This is where medications like Mounjaro, or private prescriptions, may become relevant – albeit that the cost of the latter may be a limiting factor for some. Other treatments include Orlistat, a medication that reduces fat absorption in the gut. This can be effective for some but often causes unpleasant side effects, such as oily stools and gastrointestinal upset Gastric banding or surgery may also result in significant, sustained weight loss, but they come with risks, can lead to surgical complications, and recovery can be demanding It's also important to recognise that drugs like Mounjaro aren't suitable for everyone. They can cause side effects significant enough for people to stop using them, and in some cases, they may not work at all. In this new era of faster, medication-assisted weight loss, we must remember that long-term change is about more than quick fixes. Sustainable success comes from consistent effort, willingness to change and methods that are both practical and lasting. Medications can help, sometimes dramatically, but they're not the only answer. A return to basics, with tailored support and realistic goals, remains as relevant as ever. So whether you qualify for Mounjaro, are trying lifestyle changes, or are exploring other options, remember this: the journey to better health is personal, gradual and worth it. This article is republished from The Conversation under a Creative Commons license. Read the original article. Dan Baumgardt does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.
